colistin Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Colistimethate is a methanesulfonate of polymyxin antibacterial colistin. Colistimethate is a nonactive prodrug. In aqueous solutions, colistimethate is hydrolyzed and forms a complex mixture of partially sulfomethylated derivatives and colistin. The antimicrobial activity of colistin is similar to that of polymyxin B and is restricted to gram-negative bacteria, including P aeruginosa, Acinetobacter species, Enterobacter-Klebsiella tribe, Escherichia coli, Salmonella and Shigella species, Citrobacter species, Yersinia pseudotuberculosis, Morganella morganii and Haemophilus influenzae. Colistin has also been shown to possess considerable in vitro activity against Stenotrophomonas maltophilia. Colistin and polymyxin B, however, do not have activity against Proteus, Providencia, Serratia species, Pseudomonas mallei, Burkholderia cepacia, Brucella species, most gram-positive bacteria, gram-negative cocci, anaerobes, fungi and parasites. Parenteral or nebulized colistimethate is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.   NCATS

Chemistry

  • SMILES: CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O
  • InChIKey: JORAUNFTUVJTNG-BSTBCYLQSA-N
  • Mol. Mass: 2296.97
  • ALogP: -3.14
  • ChEMBL Molecules:
    colistin  
    colistimethate sodium  
    polymyxin e  
    colistin sulfate  
    colistimethate  
    colistin  
    colimycin  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$3.7300 - $12.1333
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( urea, thonzonium bromide, neomycin, colistin )

Alternative names

colifin 1 miu | colifin 2 miu | colimycin | colimycin m | colimycin sodium methanesulfonate | colistimethate | colistimethate, disodium salt | colistimethate sodium | colistin | colistina | colistin (colistimethate) | colistine | colistin methanesulfonate sodium | colistin methanesulfonic acid | colistinmethanesulfonic acid | colistin sodium methanesulfonate | colistins sulfate | colistin sulfate | colistin sulfomethate | colistin sulphate | colistin sulphomethate | colistinum | colobreathe | colomycin | coly-mycin | coly-mycin m | coly-mycin s | pentasodium colistinmethanesulfonate | polymyxin e | promixin | w-1929

Organizations (91)

Research & Development (79)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (40)

Approved Indications (3)


 

Bacterial Infections (approved 1962)

Gram-Negative Bacterial Infections (approved 1970)

Infections

Experimental Indications - Clinical Trial Phases 1-4 (40)


 

Abdominal Injuries (Phase 3)

Acinetobacter baumannii (Phase 3)

Acinetobacter Infections (Phase 4)

Acute Kidney Injury (Phase 3)

Bacteremia (Phase 3)

Bacterial Infections (Phase 4)

Blood-Borne Infections (Phase 3)

Bronchiectasis (Phase 4)

Bronchitis (Phase 3)

Colistin (Phase 4)

Colorectal Neoplasms (Phase 4)

Communicable Diseases (Phase 4)

Critical Illness (Phase 4)

Cross Infection (Phase 4)

Cystic Fibrosis (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Drug Resistance, Bacterial (Phase 4)

Drugs, Investigational (Phase 3)

Gram-Negative Bacteria (Phase 1)

Gram-Negative Bacterial Infections (Phase 4)

Healthcare-Associated Pneumonia (Phase 3)

Healthy Volunteers (Phase 1)

Hepatic Encephalopathy (Early Phase 1)

Infections (Phase 4)

Intestinal Neoplasms (Phase 2)

Kidney Diseases (Phase 3)

Klebsiella pneumoniae (Phase 4)

Lymphoma (Phase 4)

Neoplasms (Phase 2/Phase 3)

Pharmacological and Toxicological Phenomena (Phase 3)

Pneumococcal Infections (Phase 1)

Pneumonia (Phase 3)

Pneumonia, Bacterial (Phase 3)

Pneumonia, Ventilator-Associated (Phase 4)

Pseudomonas aeruginosa (Phase 2)

Pseudomonas Infections (Phase 1)

Pyelonephritis (Phase 3)

Sepsis (Phase 3)

Shock, Septic (Phase 3)

Urinary Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 67
  • # of Trial Organizations: 79

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue